2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Immunology, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3642 High-dose methotrexate–based induction followed by myeloablative consolidation achieves real-world outcomes comparable to alliance 51101 in primary cns lymphoma

Akhil Kesaraju, BA, Jeevan Rajkumar, BA2, Shahzeem Bhayani, MD3, Marcus Watkins, PhD4, Armin Ghobadi, MD5, Todd Fehniger, MD, PhD6, Neha Mehta-Shah, MD, MSCI7, Amanda Cashen, MD8, Brad S. Kahl, MD9, Nancy L. Bartlett, MD10, David Aaron Russler-Germain, MD, PhD11
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
8 Washington University School of Medicine, St. Louis, Missouri, United States
9 Washington University School of Medicine, St. Louis, Missouri, United States
10 Washington University School of Medicine, St. Louis, Missouri, United States
11 Washington University School of Medicine, St. Louis, Missouri, United States

Background: Primary CNS Lymphoma (PCNSL) is an aggressive malignancy often associated with poor outcomes, but frontline high-dose methotrexate (HD-MTX)-based treatment offers curative potential for many patients. Early data from the Alliance 51101 study demonstrated prolonged survival after HD-MTX-based induction followed by myeloablative (MA) consolidation, which motivated institutional practice change at our center. Here, we describe the real-world outcomes of patients with newly diagnosed PCNSL treated with HD-MTX-based induction, with a focus on patients who received consolidative MA autologous stem cell transplantation (ASCT) per the 51101 approach. 

Methods: This single-center, retrospective study included patients aged 18-75 diagnosed with PCNSL between 1/1/2018 and 1/1/2025 who received ≥1 cycle of HD-MTX at our institution, defined as ≥3 g/m² (before renal dose adjustment). Responses were assessed using International PCNSL Collaborative Group criteria. Adverse events (AEs) of interest (transaminitis, cytopenia, mucositis, kidney injury) were graded per CTCAE v5. The Kaplan-Meier method was used for time-to-event analysis, with data cutoff of July 1, 2026. Progression-free survival (PFS) was measured as time from diagnosis to either disease progression or death, with censoring for therapy changes due to poor treatment response or toxicity. Overall survival (OS) was measured as time from diagnosis to death irrespective of cause. 

Results: Among 72 patients, median age at diagnosis was 64 years (range: 29-75). 55.6% (n=40) were male. Most patients identified as White (88.9%, n=64), followed by Black (8.3%, n=6), and Asian (2.8%, n=2); one patient identified as Hispanic (1.4%, n=1).  Supratentorial disease was the most common site of involvement (91.7%, n=66), followed by posterior fossa (26.4%, n=19), leptomeninges (5.6%, n=4), and eyes (4.2%, n=3). 21 patients (29.2%) had more than one site of involvement. Cell-of-origin (COO) was non-germinal center in 72.2% (n=52) and germinal center in 19.4% (n=14) of patients; 6 patients (8.3%) had unknown COO. 

For induction therapy, 86.1% (n=62) of patients received HD-MTX, rituximab, and temozolomide, while 12.5% (n=9) received HD-MTX and rituximab, and one patient (1.4%) received only HD-MTX. Most patients (n=57, 79.2%) received ≥5 cycles of HD-MTX during induction (range: 1-8). The median number of HD-MTX doses was 5 (IQR: 5-6) and median dosage was 3.5 g/m² (IQR: 3-3.5), both lower than Alliance 51101 (8 doses, 8 g/m²). 65.3% (n=47) of patients experienced at least one grade ≥3 AE of interest, most commonly transaminitis (n=29, 40.3%) followed by neutropenia (n=24, 33.3%) and anemia (n=16, 22.2%). HD-MTX dose reductions occurred in 51.4% (n=37) of patients, but only 2 patients (2.8%) required glucarpidase. 51 patients (70.8%) received high-dose cytarabine (HiDAC) during induction after completing HD-MTX. Overall response rate (ORR) following induction was 90.3% (n=65, 95% CI 81–96%), and complete response rate (CRR) following induction was 54.2% (n=39, 95% CI 42–66%).  

Post-induction (HD-MTX +/- HiDAC) management consisted of MA ASCT in 65.3% (n=47), maintenance therapy in 9.7% (n=7), non-MA consolidation with etoposide + cytarabine in 2.8% (n=2), and surveillance alone in 22.2% (n=16). Conditioning for MA-ASCT consisted of thiotepa/carmustine in 95.7% (n=45) and thiotepa/busulfan/cyclophosphamide in 4.3% (n=2). Maintenance therapy included temozolomide (n=4, 57.1%), HD-MTX (n=2, 28.6%), and lenalidomide (n=1, 14.3%). Median follow-up was 3.3 years.  

In the full cohort, 2-year PFS was 71.8% (95% CI 62–83%) and 2-year OS was 81.5% (95% CI 73–91%). Median PFS was 6.4 years (95% CI 4.7–not reached) and median OS was 7.7 years (95% CI 7.7–not reached). By consolidation strategy, patients who completed ASCT had 2-year PFS of 80.7% (95% CI 70.1–92.9%) and 2-year OS of 89.1% (95% CI 80.5–98.6%), while those who did not had 2-year PFS of 54.6% (95% CI 37.9–78.8%) and 2-year OS of 66.9% (95% CI 50.4–88.7%). These results were comparable to Alliance 51101: the MA and non-MA arms reported 2-year PFS of 73% vs 51% and 2-year OS of 87% vs 78%, respectively. 

Conclusion: In this real-world cohort of patients with PCNSL receiving HD-MTX-based induction, response rates and survival outcomes were comparable to findings from Alliance 51101, supporting adoption of this treatment paradigm and clarifying the efficacy and safety profile of the 51101 approach outside of a clinical trial. 

Akhil Kesaraju, BA: No relevant conflicts of interest to declare.